Metadoxine accelerates fatty liver recovery in alcoholic patients: Results of a randomized double-blind, placebo-control trial

Journal of Hepatology

Volumn 28, Issue 1, 1998, Pages 54-60

  Caballería, Joan ^a   Parés, Albert ^a   Brú, Concepció ^a   Mercader, José ^b   Plaza, Antonio Garcia ^c   Caballería, Llorenç ^a   Clemente, Gerardo ^d   Rodrigo, Luis ^e   Rodés, Joan ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Alcoholic liver disease; Metadoxine; Steatosis; Ultrasonography

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; METADOXINE;

ADULT; AGED; ALCOHOL CONSUMPTION; ALCOHOLISM; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ECHOGRAPHY; FATTY LIVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEATOSIS;

EID: 0031888387     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80202-X     Document Type: Article

References (36)

1. Mezey E. Treatment of alcoholic liver disease. Semin LIver Dis. 13:1993;210-216.
2. Leevy CM. Fatty Liver: a study of 270 patients with biopsy proven fatty liver and a review of the literature. Medicine. 41:1962;249-276.
3. Sorensen TIA, Orholm M, Bentsen KD, Hoybe G, Eghoje K, Christoffersen P. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictor of alcohol cirrhosis. Lancet. ii:1984;241-244.
4. Worner TM, Lieber CS. Perivenular fibrosis as a precursor lesion of cirrhosis. JAMA. 254:1985;627-630.
5. Teli MR, Day CP, Burt AD, Bennett MK, James OFW. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet. 346:1995;987-990.
6. Kawase T, Kato S, Lieber CS. Lipid peroxidation and antioxidant defence system in rat liver after chronic ethanol feeding. Hepatology. 10:1989;818-821.
7. Calabrese V, Calderone A, Ragusa N, Rizza V. Effects of Metadoxine on cellular status of glutathione and on enzymetric defence system following acute ethanol intoxication in rats. Drugs Exp Clin Res. XXII:1996;17-24.
8. Ragusa N, Zito D, Vanella A, Bondi C, Rizza V. Effects of pyridoxine on hepatic tryptophan pyrrolase activity during chronic ethanol administration. Biochem Exp Biol. 6:1980;391-394.
9. Bousquet E, Guarcello V, Morale MC, Rizza V. Analysis of 5-pyrrolidone-2-carboxylate ester by reverse phase high performance liquid chromatoraphy. Anal Biochem. 131:1983;135-140.
10. Meister A. Glutathione metabolism and its selective modification. J Biol Chem. 263:1988;17205-17208.
11. Felicioli R, Saracchi I, Flagiello M, Bartoli C. Effects of pyridoxine-pyrrolidone carboxylate on hepatic and cerebral ATP levels in ethanol treated rats. Int J Clin Pharmacol Ther Toxicol. 6:1980;277-280.
12. Calabrese V, Ragusa N, Rizza V. Effect of pyrrolidone carboxylate (PCA) and pyridoxine on liver ethanol metabolism during chronic ethanol intake in rats. Int J Tissue React. XVII:1995;15-20.
13. Parés X, Moreno A, Peralba J, Font M, Bruseghini L, Esteras A. Action of Metadoxine on isolated human and rat alcohol and aldehyde dehydrogenases. Effects on enzymes in chronic ethanol-fed rats. Methods Find Exp Clin Pharmacol. 13:1991;37-42.
14. Annoni G, Khlat B, Lampertico P, Dell'Oca M, Dioguardi FS. Metadoxine (Metadoxil*) inalcoholic liver diseases. Clin Trial J. 25:1988;333-341.
15. Corsini G, Gelso E, Giuliano G. Effetti della metadoxina sulle principali alterazioni bio-umorali indotte dall'etilismo cronico. Clin Ter. 140:1992;251-2575.
16. Saverymuttu SH, Joseph AEA, Maxwell JC. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J. 292:1986;13-15.
17. Osawa H, Mori Y. Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical amplitudes. J Clin Ultrasound. 24:1996;25-29.
18. Boloni L, Gaiani S, Barbara L. Liver and portal hypertension. Taylor KJW, Burn PN, Wells PNT. Clinical Applications of Doppler Ultrasound. 1995;Raven Press, New York.
19. Caballería J, Torres M, Camps J, Parés A, Reixach M, Rodés J. Urine alcohol assessment: a helpful method for controlling abstinence in alcoholic liver disease. Alcohol Alcohol. 23:1988;403-407.
20. Friedman SL. Cellular sources of collagen and regulation of collagen production in liver. Semin Liver Dis. 10:1990;20-29.
21. Matsuoka M, Zhang MY, Tsukamoto H. Sensitization of hepatic lipocytes by high fat diet stimulatory effects of Kupffer cell-derived factors: implications for fibrogenesis. Hepatology. 11:1990;173-182.
22. Reeves HL, Burt AD, Wood S, Day CP. Hepatic stellate cell activation occurs in the absence of hepatitis alcoholic liver disease and correlates with the severity of steatosis. J Hepatol. 25:1996;677-683.
23. Lattéron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol. 24:1996;200-208.
24. Kamimura S, Gaal K, Britton RS, Bacon BR, Triadafilopoulos G, Tsukamoto H. Increased 4-hydroxynonenal levels in experimental alcoholic liver disease: association of lipid peroxidation with liver fibrogenesis. Hepatology. 16:1992;448-453.
25. Parola M, Pinzani M, Casini A, Albano E, Poli G, Gentilini A, et al. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen α (1) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun. 194:1993;1044-1050.
26. Lieber CS. Alcohol and the liver: 1994 update. Gastroenterology. 106:1994;1044-1050.
27. MacSween RNM, Burt AD. Histological spectrum of alcoholic liver disease. Semin Liver Dis. 6:1986;221-232.
28. Lewis E. Screening for diffuse and focal liver disease: the case for hepatic sonography. J Clin Ultrasound. 12:1984;67-73.
29. Sandford NL, Walsh P, Matis C, Baddeley H, Powell LM. Is ultrasdonography useful in the assessment of diffuse parenchymal liver diasese? Gastroenterology. 89:1985;186-191.
30. Medhat A, Iber FL, Dunne M. A new quantitative ultrasonic method for diagnosis of chronic eparenchymal liver disease. Gastroenterology. 94:1988;157-162.
31. Martinez-Noguera A, Calonge E, Coscojuela P, Soriano G, Marti-Vicente A, Teixidó M. Chronic liver disease: comparison of ultrasound patterns with laparoscopy and biopsy. J Clin Ultrasound. 21:1993;325-330.
32. Schäfer C, Greiner B, Landig J, Feil E, Schütz ET, Bode JC, et al. Decreased endotoxin-binding capacity of whole blood in patients with alcoholic liver disease. J Hepatol. 26:1997;567-573.
33. Debongnie JC, Pauls C, Fievez M, Wibin E. Prospective evaluation of the diagnostic accuracy of liver ultrasonography. Gut. 22:1981;130-135.
34. Meek DR, Mills PR, Gray HW, Duncan JG, Rusell RI, McKillop JH. A comparison of computer tomography, ultrasound and scintigraphy in the diagnosis of alcoholic liver disease. Br J Radiol. 57:1984;23-27.
35. Annoni G, Contu L, Tronci MA, Caputo A, Arosio B. Pyridoxol L, 2-pyrrolidon-5 carboxylate prevents active fibroplasia in CC14-treated rats. Pharmacol Res. 25:1992;87-93.
36. 4-induced liver fibrosis: effect of pyridoxol L, 2-pyrrolidon-5 carboxylate. Pharmacol Toxicol. 73:1993;301-304.